|
Title
|
|
|
|
BDCA1+CD14+ immunosuppressive cells in cancer, a potential target?
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Dendritic cell (DC) vaccines show promising effects in cancer immunotherapy. However, their efficacy is affected by a number of factors, including (1) the quality of the DC vaccine and (2) tumor immune evasion. The recently characterized BDCA1+CD14+ immunosuppressive cells combine both aspects; their presence in DC vaccines may directly hamper vaccine efficacy, whereas, in patients, BDCA1+CD14+ cells may suppress the induced immune response in an antigen-specific manner systemically and at the tumor site. We hypothesize that BDCA1+CD14+ cells are present in a broad spectrum of cancers and demand further investigation to reveal treatment opportunities and/or improvement for DC vaccines. In this review, we summarize the findings on BDCA1+CD14+ cells in solid cancers. In addition, we evaluate the presence of BDCA1+CD14+ cells in leukemic cancers. Preliminary results suggest that the presence of BDCA1+CD14+ cells correlates with clinical features of acute and chronic myeloid leukemia. Future research focusing on the differentiation from monocytes towards BDCA1+CD14+ cells could reveal more about their cell biology and clinical significance. Targeting these cells in cancer patients may improve the outcome of cancer immunotherapy. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Vaccines
| |
|
Publication
|
|
|
|
Basel
:
Mdpi
,
2018
| |
|
ISSN
|
|
|
|
2076-393X
| |
|
DOI
|
|
|
|
10.3390/VACCINES6030065
| |
|
Volume/pages
|
|
|
|
6
:3
(2018)
, 10 p.
| |
|
Article Reference
|
|
|
|
65
| |
|
ISI
|
|
|
|
000448337100004
| |
|
Pubmed ID
|
|
|
|
30235890
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|